Gut Microbiota, Prebiotics, Probiotics, and Synbiotics in Gastrointestinal and Liver Diseases: Proceedings of a Joint Meeting of the Brazilian Society of Hepatology (Sbh), Brazilian Nucleus for the Study of Helicobacter Pylori and Microbiota (Nbehpm), and Brazilian Federation of Gastroenterology (Fbg)

Schiavon, Leonardo Lucca; Oliveira, Cláudia Pinto Marques Souza de; Álvares‐da‐Silva, Mário Reis; Sassaki, Lígia Yukie; Passos, Maria do Carmo Friche; Farias, Alberto Queiróz; Barros, Luísa Leite; Barreto, Bruno Paes; Albuquerque, Gisela de Melo Lins de Bandeira; Alves, Amanda Mandarino; Navarro–Rodriguez, Tomás; Bittencourt, Paulo Lisboa

doi:10.1590/s0004-2803.202000000-72

Cited by 5 publications

(6 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirmed that SIBO is significantly associated with liver disease. This finding is in agreement with previous reports from the literature ( 32 – 36 ). However, SIBO prevalence in NAFLD is significantly variable, ranging between 17, 26.2, and 60% according to the reports ( 32 – 37 ).…”

Section: Discussionsupporting

confidence: 94%

“…This finding is in agreement with previous reports from the literature ( 32 – 36 ). However, SIBO prevalence in NAFLD is significantly variable, ranging between 17, 26.2, and 60% according to the reports ( 32 – 37 ). More recently, Guimaraes et al described SIBO prevalence in a population of patients with NAFLD to be of 26.2 % ( 18 ).…”

Section: Discussionsupporting

confidence: 94%

“…Several scientific reports showed an association between gut microbiota derangement and liver diseases derived from viral hepatitis, cholangiopathies, autoimmunity, alcohol abuse, and, more recently, altered metabolism ( 13 , 32 – 35 ). Since the prevalence of liver diseases of viral origin (especially HCV infection) has significantly dropped because of the use of direct-acting antivirals worldwide ( 35 ), we focused our attention mainly on metabolic and/or alcoholic causes of liver disease (NAFLD and ALD).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study

et al. 2022

View full text Add to dashboard Cite

IntroductionGut microbiota are a complex ecosystem harboring our intestine. They maintain human body equilibrium, while their derangement, namely, “dysbiosis“, has been associated with several gastrointestinal diseases, such as liver steatosis (NAFLD) and liver cirrhosis. Small intestinal bacterial overgrowth (SIBO) is an example of dysbiosis of the upper gastrointestinal (GI) tract.AimThe aim of this study is to evaluate the relationship between SIBO and levels of endotoxemia and grade of liver steatosis (LS) and liver fibrosis (LF) in hepatologic patients.Materials and MethodsConsecutive outpatients referred to our hepatology clinic were tested for SIBO by the lactulose breath test (LBT) and peripheral blood levels of endotoxemia; LS grading and LF were assessed by abdominal ultrasound and transient elastography, respectively.ResultsFifty-two consecutive patients (17 with alcohol abuse (4.5 ± 0.8 alcohol units per day), 4 with HCV and 2 with HBV infection, 24 of metabolic origin, 2 of autoimmune origin, and 3 with cholangiopathies; mean age 54.7 ± 8.3 years, 31 F, BMI 24.1 ± 1.1 Kg/m2) and 14 healthy volunteers (HV) (mean age 50.1 ± 4.3 years, 9 F, BMI 23.3 ± 1.1 Kg/m2) were enrolled. SIBO prevalence was significantly higher in cirrhotic (LC) vs. non-cirrhotic (LNC) patients and vs. HV (all, p < 0.05), with a significant positive trend according to Child-Pugh status (all, p < 0.05). SIBO prevalence was not correlated with LS stages (all, p = NS). Consensually, endotoxin levels were significantly higher in LC vs. LNC and vs. HV (all, p < 0.05) and significantly correlated with LF in patients with LC, according to Child-Pugh status (all, p < 0.05).ConclusionThis study shows that SIBO prevalence and relative endotoxin blood levels seem to be significantly associated with the grade of LF vs. LS in LC. SIBO is also present under pre-cirrhotic conditions, but its prevalence seems to correlate with liver disease irreversible derangement.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…At the phylum level, previous work ( Sheehan, Moran & Shanahan, 2015 ; Nishida et al, 2018 ; Franzosa et al, 2019 ) have presented imbalances in IBD patients for the Firmicutes and Bacteroidetes . In IBD patients, the decrease of the bacteria with anti-inflammatory properties, such as Bifidobacteria ( Barbuti et al, 2020 ; Trop & Orel, 2014 ) has also been noted as one of the most prominent changes, in addition to the reduction of bacteria of the phylum Firmicutes ( Hold et al, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

Inflammatory bowel disease biomarkers of human gut microbiota selected via different feature selection methods

Bakır-Güngör

Hacılar

Jabeer

et al. 2022

PeerJ

View full text Add to dashboard Cite

The tremendous boost in next generation sequencing and in the “omics” technologies makes it possible to characterize the human gut microbiome—the collective genomes of the microbial community that reside in our gastrointestinal tract. Although some of these microorganisms are considered to be essential regulators of our immune system, the alteration of the complexity and eubiotic state of microbiota might promote autoimmune and inflammatory disorders such as diabetes, rheumatoid arthritis, Inflammatory bowel diseases (IBD), obesity, and carcinogenesis. IBD, comprising Crohn’s disease and ulcerative colitis, is a gut-related, multifactorial disease with an unknown etiology. IBD presents defects in the detection and control of the gut microbiota, associated with unbalanced immune reactions, genetic mutations that confer susceptibility to the disease, and complex environmental conditions such as westernized lifestyle. Although some existing studies attempt to unveil the composition and functional capacity of the gut microbiome in relation to IBD diseases, a comprehensive picture of the gut microbiome in IBD patients is far from being complete. Due to the complexity of metagenomic studies, the applications of the state-of-the-art machine learning techniques became popular to address a wide range of questions in the field of metagenomic data analysis. In this regard, using IBD associated metagenomics dataset, this study utilizes both supervised and unsupervised machine learning algorithms, (i) to generate a classification model that aids IBD diagnosis, (ii) to discover IBD-associated biomarkers, (iii) to discover subgroups of IBD patients using k-means and hierarchical clustering approaches. To deal with the high dimensionality of features, we applied robust feature selection algorithms such as Conditional Mutual Information Maximization (CMIM), Fast Correlation Based Filter (FCBF), min redundancy max relevance (mRMR), Select K Best (SKB), Information Gain (IG) and Extreme Gradient Boosting (XGBoost). In our experiments with 100-fold Monte Carlo cross-validation (MCCV), XGBoost, IG, and SKB methods showed a considerable effect in terms of minimizing the microbiota used for the diagnosis of IBD and thus reducing the cost and time. We observed that compared to Decision Tree, Support Vector Machine, Logitboost, Adaboost, and stacking ensemble classifiers, our Random Forest classifier resulted in better performance measures for the classification of IBD. Our findings revealed potential microbiome-mediated mechanisms of IBD and these findings might be useful for the development of microbiome-based diagnostics.

show abstract

“…Generally speaking, initial investigation for the diagnosis of liver cirrhosis includes serologies for viral hepatitis, ferritin, transferrin saturation and abdominal ultrasound, as well as complete blood count, liver function tests, and international normalized prothrombin time/ratio, if not yet requested. Additional tests are based on demographic data and risk factors (BARBUTI et al, 2020;FU et al, 2017;JIŘÍ et al, 2016;LURIE et al, 2015;MACHADO et al, 2020). (GUERRA et al, 2015;HONAR et al, 2015;RAMALHO et al, 2017;SCHMILLEVITCH et al, 2016).…”

Section: Recent Advances In the Diagnosis Of Liver Cirrhosismentioning

confidence: 99%

Advances in the diagnosis and therapy of liver cirrhosis: a systematic review / Avanços no diagnóstico e terapia da cirrose hepática: uma revisão sistemática

Vasconcelos¹,

Oliveira²,

Barbosa³

et al. 2021

BJDV

View full text Add to dashboard Cite

Hepatic cirrhosis (HC) is a diffuse pathophysiological state of the liver considered to be the end-stage of several liver injuries. It is essential to highlight the need to implement new diagnostic and treatment methods to contain subsequent damage to liver cirrhosis, so that we can better understand the pathophysiological process of the disease and obtain better therapeutic results. Thus, this study aimed to identify advances in diagnostic methods and treatments for liver cirrhosis. This is a systematic literature review study, conducted by searching the descriptors “Liver cirrhosis”, “Alcoholic liver cirrhosis”, “Liver fibrosis” and “Liver”, in the databases: Scielo- Scientific Electronic Library Online, Lilacs - Latin American and Caribbean Center on Health Sciences Information, NIH-NCBI-Pubmed- National Center for Biotechnological Information – National Library of Medicine, following a search strategy according to descriptors in Portuguese and English, years 2015 to 2021. At the end of the search with the descriptors, 835 articles were found in the databases, of which 88 were in the Scielo platform, 286 in Lilacs and 461 in Pubmed. After the three selection steps, 811 articles were excluded and 23 articles that met the inclusion and exclusion criteria were selected for analysis. Based on this systematic review, it is pointed out that there has been a lot of development regarding the diagnosis and treatment of cirrhosis that, for many years, required scientific evidence to combat morbidity and mortality and reverse the condition of liver cirrhosis.

show abstract

Cited by 5 publications

References 218 publications

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study

Inflammatory bowel disease biomarkers of human gut microbiota selected via different feature selection methods

Advances in the diagnosis and therapy of liver cirrhosis: a systematic review / Avanços no diagnóstico e terapia da cirrose hepática: uma revisão sistemática

Contact Info

Product

Resources

About